|
Jun 27
|
Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit
|
|
May 13
|
Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
May 12
|
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
|
|
Apr 7
|
Pharvaris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Apr 1
|
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
|